Physician profile
Michael Cooney
NPI 1073548434
$397,707.08
in general payments reported to CMS, 2019-2025
13 companies · $18K in 2025
The $18K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $28K · 2021: $41K · 2022: $98K · 2023: $136K · 2024: $54K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $174K · Travel and Lodging: $18K · Food and Beverage: $4,521 · Honoraria: $4,500 · Consulting Fee: $3,024 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $174,007.61 |
| Travel and Lodging | $18,490.40 |
| Food and Beverage | $4,521.07 |
| Honoraria | $4,500.00 |
| Consulting Fee | $3,024.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $205,910.09 | 2020-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $115,366.67 | 2019-2025 | Vabysmo, Lucentis |
| Apellis Pharmaceuticals, INC. | $52,004.63 | 2022-2025 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13,532.25 | 2019 | |
| Genentech, INC. | $7,850.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $2,277.92 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $235.91 | 2025 | Xdemvy |
| Alcon Vision LLC | $159.16 | 2024-2025 | Eysuvis, Tryptyr, Rocklatan |
| Astellas Pharma US INC | $107.12 | 2025 | Izervay |
| Abbvie INC. | $102.84 | 2025 | |
| Bausch & Lomb Americas INC. | $78.59 | 2025 | Miebo, Vyzulta |
| Amgen INC. | $66.48 | 2024-2025 | Tepezza |
| Thea Pharma INC. | $15.42 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cooney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.